OTCHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
maintain Nasdaq listing compliance | A primary condition in SCWORX CORP's published investment case. The stated target is closing bid price above Nasdaq minimum for 30 consecutive days. | Under Pressure | failure to meet Nasdaq listing price requirements | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
move towards profitability | A primary condition in SCWORX CORP's published investment case. The stated target is move from loss-making to positive operating income. | Improving | operating losses widen or no improvement next year | Operating income: $-120,954 FY2026-Q2; GAAP. Published target: move from loss-making to positive operating income. Target period is not explicitly aligned with this observation. Source published Aug 14, 2026-120,954 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8b67b21b-bd04-4019-9568-3aa9fd26f121. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
stabilize or grow revenue | A primary condition in SCWORX CORP's published investment case. The stated target is >=0% YoY revenue growth. | Intact | YoY revenue growth falls below -1% next year | Revenue growth: 3.43% FY2026-Q2; GAAP. Published target: >=0% YoY revenue growth. Target period is not explicitly aligned with this observation. Source published Aug 14, 20263.430399 percent · calculatedSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8b67b21b-bd04-4019-9568-3aa9fd26f121. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth and recovery story, not a proven durable compounder. The thesis is currently intact, but the evidence is mixed and confidence is medium.
The valuation evidence points to WORX being cheap versus peers, while the model also shows a peer premium and has low confidence. The negative expectations gap suggests expectations are subdued, but the snapshot does not establish precisely what investors assume about future growth.
Near term, results show no clear revenue growth trend, with quarterly revenue around $700,000 and gross profit fluctuating without clear improvement. Management has restored Nasdaq compliance, but continued listing has conditions, including monitoring and monthly reporting. The business remains loss-making, and execution on customer relationships and the platform is mixed.
Over the next one to three years, the thesis hinges on whether management can turn its customer and platform priorities into steadier growth and stronger gross profit. A weakening jobs trend could pressure cyclical healthcare names, while continued earnings strength from sector bellwethers could sustain a supportive backdrop. Misses or lower guidance from those companies could remove that support.
The long-term thesis remains intact, but the evidence for a durable growth path is limited and listing oversight remains a near-term risk. The multi-year view depends on execution and the healthcare sector backdrop. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.